Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 2
1979 1
1980 3
1981 2
1983 5
1984 2
1985 6
1986 2
1987 13
1988 4
1989 22
1990 11
1991 19
1992 9
1993 16
1994 11
1995 21
1996 17
1997 26
1998 25
1999 15
2000 7
2001 11
2002 11
2003 14
2004 10
2005 4
2006 9
2007 9
2008 2
2009 5
2010 8
2011 5
2012 3
2013 3
2014 4
2015 5
2016 1
2017 2
2018 2
2020 2
2021 2
2022 2
2025 3
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

346 results

Results by year

Filters applied: . Clear all
Page 1
An open-randomized clinical trial of selegiline in amyotrophic lateral sclerosis.
Mazzini L, Testa D, Balzarini C, Mora G. Mazzini L, et al. J Neurol. 1994 Feb;241(4):223-7. doi: 10.1007/BF00863772. J Neurol. 1994. PMID: 8195821 Clinical Trial.
Fifty-three patients were randomly assigned to receive the drug (selegiline 10 mg/day orally for 6 months) and the remaining 58 were considered ALS controls. ...Our data do not show any significant effect of selegiline in modifying the progression of ALS....
Fifty-three patients were randomly assigned to receive the drug (selegiline 10 mg/day orally for 6 months) and the remaining 58 were …
A phase 1 trial of pharmacologic interactions between transdermal selegiline and a 4-hour cocaine infusion.
Harris DS, Everhart T, Jacob P 3rd, Lin E, Mendelson JE, Jones RT. Harris DS, et al. BMC Clin Pharmacol. 2009 Aug 1;9:13. doi: 10.1186/1472-6904-9-13. BMC Clin Pharmacol. 2009. PMID: 19646280 Free PMC article. Clinical Trial.
This study evaluated the safety of and pharmacologic interactions between 7 days of transdermal selegiline dosed with patches (Selegiline Transdermal System, STS) that deliver 6 mg/24 hours and 2.5 mg/kg of cocaine administered over 4 hours. ...No serious adverse ef …
This study evaluated the safety of and pharmacologic interactions between 7 days of transdermal selegiline dosed with patches (Sel …
Selegiline in adults with attention deficit hyperactivity disorder: clinical efficacy and safety.
Ernst M, Liebenauer LL, Jons PH, Tebeka D, Cohen RM, Zametkin AJ. Ernst M, et al. Psychopharmacol Bull. 1996;32(3):327-34. Psychopharmacol Bull. 1996. PMID: 8961775 Clinical Trial.
Clinical effects of high-dose and low-dose selegiline treatment were examined in 24 adults with attention deficit hyperactivity disorder (ADHD). ...There was a significant effect of Time, indicating decreased ADHD symptom severity scores in all three groups. Selegiline …
Clinical effects of high-dose and low-dose selegiline treatment were examined in 24 adults with attention deficit hyperactivity disor …
Transdermal selegiline and intravenous cocaine: safety and interactions.
Houtsmuller EJ, Notes LD, Newton T, van Sluis N, Chiang N, Elkashef A, Bigelow GE. Houtsmuller EJ, et al. Psychopharmacology (Berl). 2004 Feb;172(1):31-40. doi: 10.1007/s00213-003-1616-6. Epub 2003 Nov 6. Psychopharmacology (Berl). 2004. PMID: 14605792 Clinical Trial.
CONCLUSIONS: The combined administration of the transdermal selegiline patch and up to 40 mg cocaine was well tolerated. Selegiline may reduce physiological and subjective effects of cocaine. A randomized trial is needed to evaluate the efficacy of selegiline …
CONCLUSIONS: The combined administration of the transdermal selegiline patch and up to 40 mg cocaine was well tolerated. Selegilin …
Selegiline in comparison with methylphenidate in attention deficit hyperactivity disorder children and adolescents in a double-blind, randomized clinical trial.
Mohammadi MR, Ghanizadeh A, Alaghband-Rad J, Tehranidoost M, Mesgarpour B, Soori H. Mohammadi MR, et al. J Child Adolesc Psychopharmacol. 2004 Fall;14(3):418-25. doi: 10.1089/cap.2004.14.418. J Child Adolesc Psychopharmacol. 2004. PMID: 15650498 Clinical Trial.
OBJECTIVES: The aim of this study was to examine the selegiline treatment compared to methylphenidate (MPH) in children and adolescents with attention deficit hyperactivity disorder (ADHD). ...CONCLUSION: Following the trial, MPH did not effect greater mean improvement as …
OBJECTIVES: The aim of this study was to examine the selegiline treatment compared to methylphenidate (MPH) in children and adolescen …
Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry.
Ben-Shlomo Y, Churchyard A, Head J, Hurwitz B, Overstall P, Ockelford J, Lees AJ. Ben-Shlomo Y, et al. BMJ. 1998 Apr 18;316(7139):1191-6. doi: 10.1136/bmj.316.7139.1191. BMJ. 1998. PMID: 9583926 Free PMC article. Clinical Trial.
OBJECTIVE: To determine whether the excess mortality observed in patients who received both levodopa and selegiline in a randomised trial could be explained by revised diagnosis of Parkinson's disease, autonomic or cardiovascular effects, more rapid disease progression, or …
OBJECTIVE: To determine whether the excess mortality observed in patients who received both levodopa and selegiline in a randomised t …
A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder.
Amsterdam JD. Amsterdam JD. J Clin Psychiatry. 2003 Feb;64(2):208-14. doi: 10.4088/jcp.v64n0216. J Clin Psychiatry. 2003. PMID: 12633131 Clinical Trial.
BACKGROUND: The monoamine oxidase (MAO) inhibitor selegiline has demonstrated antidepressant efficacy superior to placebo. A selegiline transdermal system (STS) has been developed with unique pharmacokinetic and pharmacodynamic properties that allow inhibition of ce …
BACKGROUND: The monoamine oxidase (MAO) inhibitor selegiline has demonstrated antidepressant efficacy superior to placebo. A seleg …
Fluoxetine and selegiline--lack of significant interaction.
Waters CH. Waters CH. Can J Neurol Sci. 1994 Aug;21(3):259-61. doi: 10.1017/s031716710004124x. Can J Neurol Sci. 1994. PMID: 8000982 Clinical Trial.
The use of the combination of fluoxetine, an anti-depressant serotonin uptake inhibitor, and selegiline, a monoamine oxidase -B inhibitor, was reviewed in a large population of patients with Parkinson's disease. ...In this clinic population, fluoxetine and selegiline …
The use of the combination of fluoxetine, an anti-depressant serotonin uptake inhibitor, and selegiline, a monoamine oxidase -B inhib …
Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease.
Chrisp P, Mammen GJ, Sorkin EM. Chrisp P, et al. Drugs Aging. 1991 May;1(3):228-48. doi: 10.2165/00002512-199101030-00006. Drugs Aging. 1991. PMID: 1794016 Review.
Selegiline (deprenyl) is a selective inhibitor of cerebral monoamine oxidase type B at the dosage (10 mg/day) used in patients with Parkinson's disease. ...Indeed, if levodopa dosages are not decreased when selegiline is added to the therapeutic regimen, peak concen …
Selegiline (deprenyl) is a selective inhibitor of cerebral monoamine oxidase type B at the dosage (10 mg/day) used in patients with P …
346 results